DE60221359D1 - Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung - Google Patents

Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung

Info

Publication number
DE60221359D1
DE60221359D1 DE60221359T DE60221359T DE60221359D1 DE 60221359 D1 DE60221359 D1 DE 60221359D1 DE 60221359 T DE60221359 T DE 60221359T DE 60221359 T DE60221359 T DE 60221359T DE 60221359 D1 DE60221359 D1 DE 60221359D1
Authority
DE
Germany
Prior art keywords
antigestagenes
endometrial
shifting
infertility treatment
during infertility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60221359T
Other languages
English (en)
Other versions
DE60221359T2 (de
Inventor
Christa Hegele-Hartung
Holger Hess-Stumpp
Henning M Beier
Claudia Krusche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/801,925 external-priority patent/US20020143000A1/en
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of DE60221359D1 publication Critical patent/DE60221359D1/de
Application granted granted Critical
Publication of DE60221359T2 publication Critical patent/DE60221359T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE60221359T 2001-01-09 2002-01-09 Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung Expired - Fee Related DE60221359T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75628601A 2001-01-09 2001-01-09
US756286 2001-01-09
US801925 2001-03-09
US09/801,925 US20020143000A1 (en) 2001-01-09 2001-03-09 Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
PCT/IB2002/001764 WO2002067910A2 (en) 2001-01-09 2002-01-09 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment

Publications (2)

Publication Number Publication Date
DE60221359D1 true DE60221359D1 (de) 2007-09-06
DE60221359T2 DE60221359T2 (de) 2008-04-17

Family

ID=27116200

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60221359T Expired - Fee Related DE60221359T2 (de) 2001-01-09 2002-01-09 Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung

Country Status (25)

Country Link
US (1) US20040152684A1 (de)
EP (1) EP1365765B1 (de)
JP (1) JP2004520411A (de)
CN (1) CN1244329C (de)
AR (1) AR032390A1 (de)
AT (1) ATE367817T1 (de)
AU (1) AU2002253488B2 (de)
BG (1) BG107977A (de)
BR (1) BR0206367A (de)
CA (1) CA2433776A1 (de)
CZ (1) CZ20031864A3 (de)
DE (1) DE60221359T2 (de)
DK (1) DK1365765T3 (de)
EE (1) EE200300321A (de)
ES (1) ES2290284T3 (de)
HK (1) HK1065953A1 (de)
HR (1) HRP20030628A2 (de)
HU (1) HUP0302632A2 (de)
IL (1) IL156729A0 (de)
MX (1) MXPA03006156A (de)
NO (1) NO20033125L (de)
NZ (1) NZ526908A (de)
PL (1) PL361689A1 (de)
SK (1) SK8612003A3 (de)
WO (1) WO2002067910A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
ES2716862T3 (es) * 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
EP3214092A1 (de) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs vom selektiven progesteronrezeptormodulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-on

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19860719A1 (de) * 1998-12-23 2000-06-29 Schering Ag Neue Testosteronderivate und ihre Verwendung zur Langzeittherapie von Androgen-abhängigen Erkrankungen

Also Published As

Publication number Publication date
HRP20030628A2 (en) 2005-06-30
JP2004520411A (ja) 2004-07-08
US20040152684A1 (en) 2004-08-05
NO20033125L (no) 2003-09-09
BR0206367A (pt) 2003-12-23
CN1496263A (zh) 2004-05-12
BG107977A (bg) 2004-08-31
CA2433776A1 (en) 2002-09-06
IL156729A0 (en) 2004-02-08
PL361689A1 (en) 2004-10-04
NO20033125D0 (no) 2003-07-08
EE200300321A (et) 2003-10-15
HUP0302632A2 (hu) 2003-11-28
ES2290284T3 (es) 2008-02-16
HK1065953A1 (en) 2005-03-11
AR032390A1 (es) 2003-11-05
DE60221359T2 (de) 2008-04-17
CN1244329C (zh) 2006-03-08
SK8612003A3 (en) 2004-03-02
WO2002067910A2 (en) 2002-09-06
CZ20031864A3 (en) 2004-03-17
DK1365765T3 (da) 2007-10-29
MXPA03006156A (es) 2003-09-16
WO2002067910A3 (en) 2003-02-06
AU2002253488B2 (en) 2007-02-15
NZ526908A (en) 2005-07-29
EP1365765A2 (de) 2003-12-03
EP1365765B1 (de) 2007-07-25
ATE367817T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
DE60120114D1 (de) Verfahren zur Verbesserung der Knochenmineralisierung
DE60237905D1 (de) Set zur Entnahme von Knochenmark
DE60214477D1 (de) Implantat zur Regeneration von Knorpelgewebe
ATE376289T1 (de) Verfahren zur signalisierung von konfigurationsparametern physikalischer kanäle
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE50102926D1 (de) Verfahren zur oxidation von kohlenwasserstoffen
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE298326T1 (de) Verfahren zur epoxidierung von olefinen
ATE382631T1 (de) Verfahren zur herstellung von virusinaktiviertem humanem gammaglobulin g
DE50213709D1 (de) Verfahren zur bereitstellung von zielführungshinweisen
DE60225539D1 (de) Verfahren zur kontinuierlichen herstellung von polyarylensulfid
DE60221972D1 (de) Verfahren zur gewichtsverminderung von gipsbauplatten
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE602004018249D1 (de) Verfahren zur Dearomatisierung von Molkeprotein
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ATE480637T1 (de) Methode zur bestimmung der biologischen aktivität von difibrotid
ATE311898T1 (de) Zusammensetzungen zur entfernung von menschlichem cerumen
DE60104976D1 (de) Verfahren zur Bereitstellung von Dienstleistungen
DE60221359D1 (de) Verwendung von antigestagene zur verschiebung der endometrialen reifung wahrend infertilitätbehandlung
DE50209840D1 (de) Verfahren zur herstellung von tensidgemischen
DE50204097D1 (de) Verfahren zur ermittlung von auswirkungen von konstruktionsentscheidungen
DE50207002D1 (de) Schaltungsanordnung und verfahren zur temperaturkompensation
DE60214629D1 (de) Verfahren zur Zersetzung von Michael-Addukten
ATE297909T1 (de) Verfahren zur epoxidierung von olefinen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee